Short-Term Debt to Capital: Nexalin (NXL)

Nexalin Technology, Inc. (NXL) develops advanced painless brain stimulation devices for depression therapy, generating recurring revenue through the sale of consumables. Demand for such neurotechnologies remains independent of economic cycles and GDP growth rates. The current figure is 0.00. This chart serves as a valuation tool for the company's net debt-to-equity ratio.

To assess the long-term sustainability of Nexalin Technology, Inc. (NXL), investors analyze the ratio of short-term loans to equity, which determines the business's reliance on operational borrowing. The trend of short-term liabilities relative to equity confirms the company's financial stability, which is essential for scaling the deployment of neurostimulators in clinics and ensuring a steady revenue stream from the sale of consumables.